Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127772621 | 12777262 | 1 | I | 20160913 | 20160924 | 20160924 | EXP | BR-MLMSERVICE-20160908-0417202-1 | BR-ACCORD-044142 | ACCORD | MOTA JM, SCARANTI M, FONSECA LG, TOLOI DA, DE CAMARGO VP, MUNHOZ RR ET AL. RESPONSE TO PACLITAXEL IN AN ADULT PATIENT WITH ADVANCEDANDLT;BOLDANDGT;ANDLT;/BOLDANDGT; KAPOSIFORM HEMANGIOENDOTHELIOMA.CASE REPORTS IN ONCOLOGY. 2016; 481-487 | 36.00 | YR | M | Y | 0.00000 | 20160924 | OT | BR | BR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127772621 | 12777262 | 1 | PS | DOCETAXEL. | DOCETAXEL | 1 | 201195 | ||||||||||||
| 127772621 | 12777262 | 2 | SS | GEMCITABINE/GEMCITABINE HYDROCHLORIDE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | 1 CYCLE | 91594 | 1000 | MG/M**2 | |||||||||
| 127772621 | 12777262 | 3 | SS | IFOSFAMIDE. | IFOSFAMIDE | 1 | DIVIDED IN 5 DOSES Q21 DAYS; 3 CYCLES | U | 0 | 9000 | MG/M**2 | ||||||||
| 127772621 | 12777262 | 4 | SS | PREDNISONE/PREDNISONE ACETATE | PREDNISONE ACETATE | 1 | Oral | U | 0 | 1 | MG/KG | QD | |||||||
| 127772621 | 12777262 | 5 | SS | DOXORUBICIN/DOXORUBICIN HYDROCHLORIDE | DOXORUBICIN HYDROCHLORIDE | 1 | Q21 DAYS, 3 CYCLES | U | 0 | 60 | MG/M**2 | ||||||||
| 127772621 | 12777262 | 6 | SS | INTERFERON ALFA NOS | INTERFERON ALFA-2A OR INTERFERON ALFA-2B | 1 | U | 0 | 3000000 | IU | TIW | ||||||||
| 127772621 | 12777262 | 7 | C | PACLITAXEL/PACLITAXEL LIPOSOME | PACLITAXEL | 1 | WEEKLY; 8 CYCLES | 0 | 80 | MG/M**2 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127772621 | 12777262 | 1 | Intravascular papillary endothelial hyperplasia |
| 127772621 | 12777262 | 2 | Intravascular papillary endothelial hyperplasia |
| 127772621 | 12777262 | 3 | Intravascular papillary endothelial hyperplasia |
| 127772621 | 12777262 | 4 | Intravascular papillary endothelial hyperplasia |
| 127772621 | 12777262 | 5 | Intravascular papillary endothelial hyperplasia |
| 127772621 | 12777262 | 6 | Intravascular papillary endothelial hyperplasia |
| 127772621 | 12777262 | 7 | Intravascular papillary endothelial hyperplasia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127772621 | 12777262 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127772621 | 12777262 | Angiosarcoma | |
| 127772621 | 12777262 | Drug ineffective | |
| 127772621 | 12777262 | Drug ineffective for unapproved indication | |
| 127772621 | 12777262 | Epistaxis | |
| 127772621 | 12777262 | Gastrointestinal haemorrhage | |
| 127772621 | 12777262 | Haematotoxicity | |
| 127772621 | 12777262 | Hypofibrinogenaemia | |
| 127772621 | 12777262 | Malignant neoplasm progression | |
| 127772621 | 12777262 | Off label use | |
| 127772621 | 12777262 | Petechiae | |
| 127772621 | 12777262 | Thrombocytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127772621 | 12777262 | 1 | 201307 | 0 | ||
| 127772621 | 12777262 | 2 | 201307 | 0 | ||
| 127772621 | 12777262 | 3 | 2015 | 0 | ||
| 127772621 | 12777262 | 4 | 2014 | 0 | ||
| 127772621 | 12777262 | 5 | 2015 | 0 | ||
| 127772621 | 12777262 | 6 | 2015 | 0 | ||
| 127772621 | 12777262 | 7 | 2014 | 201410 | 0 |